Wall Street brokerages predict that Theravance Biopharma, Inc. (NASDAQ:TBPH) will announce earnings of ($1.26) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Theravance Biopharma’s earnings, with estimates ranging from ($1.27) to ($1.24). Theravance Biopharma posted earnings of ($0.73) per share in the same quarter last year, which would suggest a negative year over year growth rate of 72.6%. The business is scheduled to issue its next quarterly earnings report on Tuesday, November 14th.

On average, analysts expect that Theravance Biopharma will report full-year earnings of ($4.85) per share for the current financial year, with EPS estimates ranging from ($5.16) to ($4.51). For the next financial year, analysts anticipate that the business will post earnings of ($4.37) per share, with EPS estimates ranging from ($4.83) to ($3.82). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover Theravance Biopharma.

TBPH has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $55.00 price target on shares of Theravance Biopharma and gave the stock a “buy” rating in a research note on Wednesday, July 19th. ValuEngine upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. BidaskClub upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Needham & Company LLC restated a “buy” rating on shares of Theravance Biopharma in a research report on Wednesday, August 2nd. Finally, Zacks Investment Research upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Tuesday, September 5th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $41.63.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/16/1-26-earnings-per-share-expected-for-theravance-biopharma-inc-tbph-this-quarter-2.html.

Shares of Theravance Biopharma (NASDAQ TBPH) opened at 31.77 on Friday. Theravance Biopharma has a 52 week low of $23.15 and a 52 week high of $43.44. The company’s 50 day moving average is $29.58 and its 200-day moving average is $35.23. The stock’s market capitalization is $1.71 billion.

In other Theravance Biopharma news, Director Henrietta Fore bought 6,000 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The stock was bought at an average cost of $23.99 per share, for a total transaction of $143,940.00. Following the completion of the transaction, the director now owns 24,000 shares of the company’s stock, valued at approximately $575,760. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Rick E. Winningham bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The shares were acquired at an average price of $24.50 per share, with a total value of $245,000.00. Following the completion of the transaction, the chief executive officer now directly owns 866,377 shares of the company’s stock, valued at approximately $21,226,236.50. The disclosure for this purchase can be found here. Insiders have purchased 20,000 shares of company stock valued at $494,300 over the last 90 days. 6.10% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. American International Group Inc. boosted its position in shares of Theravance Biopharma by 16.4% in the first quarter. American International Group Inc. now owns 24,276 shares of the biopharmaceutical company’s stock worth $894,000 after purchasing an additional 3,417 shares during the period. Harvest Management LLC bought a new position in shares of Theravance Biopharma in the first quarter worth approximately $228,000. Parametric Portfolio Associates LLC boosted its position in shares of Theravance Biopharma by 3.3% in the first quarter. Parametric Portfolio Associates LLC now owns 14,090 shares of the biopharmaceutical company’s stock worth $519,000 after purchasing an additional 456 shares during the period. Geode Capital Management LLC boosted its position in shares of Theravance Biopharma by 5.8% in the first quarter. Geode Capital Management LLC now owns 330,280 shares of the biopharmaceutical company’s stock worth $12,160,000 after purchasing an additional 18,177 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Theravance Biopharma by 11.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 162,608 shares of the biopharmaceutical company’s stock worth $5,988,000 after purchasing an additional 17,136 shares during the period. Institutional investors own 84.54% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.